Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.

Tomoyoshi Kondo1

  • 1Department of Neurology, Wakayama Medical University, 811-1 Kimiidera, Wakayama 641-0035, Japan.

Journal of Neurology
|October 11, 2002
PubMed
Summary

For early Parkinson's disease, dopamine agonist (DA) therapy offers similar benefits to levodopa but with fewer motor complications. DA agonists are recommended as initial treatment due to their longer effectiveness and potential neuroprotective effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Japanese Mucuna pruriens (Hasshou Beans) Showed Fast-acting and Long-lasting Effects in Parkinson's Disease.

Internal medicine (Tokyo, Japan)·2024
Same author

The updated retrospective questionnaire study of sporadic inclusion body myositis in Japan.

Orphanet journal of rare diseases·2019
Same author

Long-Term Selegiline Monotherapy for the Treatment of Early Parkinson Disease.

Clinical neuropharmacology·2019
Same author

A Randomized Double-Blind Placebo-Controlled Phase III Trial of Selegiline Monotherapy for Early Parkinson Disease.

Clinical neuropharmacology·2017
Same author

Three-Year Follow-Up of High-Dose Ubiquinol Supplementation in a Case of Familial Multiple System Atrophy with Compound Heterozygous COQ2 Mutations.

Cerebellum (London, England)·2017
Same author

Multicenter questionnaire survey for sporadic inclusion body myositis in Japan.

Orphanet journal of rare diseases·2016

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Levodopa is crucial for advanced Parkinson's disease (PD).
  • Early-stage PD treatment involves levodopa or dopamine agonists (DA).
  • Motor complications are a significant challenge in long-term PD management.

Purpose of the Study:

  • To compare the efficacy and complication rates of DA agonists versus levodopa in early Parkinson's disease.
  • To evaluate the potential benefits of DA agonists, including neuroprotection.

Main Methods:

  • The abstract does not specify methods but discusses clinical observations and pharmacological properties.
  • Comparison of plasma half-lives and known effects on dopamine receptors.

Main Results:

  • DA agonists show similar efficacy to levodopa in early parkinsonism.

Related Experiment Videos

  • DA agonists are associated with a lower incidence of motor complications compared to levodopa over time.
  • DA agonists possess longer plasma half-lives, potentially mitigating receptor desensitization.

    • Conclusions:

    • DA agonist therapy is recommended as the initial treatment for Parkinson's disease.
    • The choice of therapy should consider individual patient conditions.
    • DA agonists may offer neuroprotective benefits, warranting further investigation.